Radioligand Therapy for HER2-Positive Cancers Enters Human Trials for First Time
Radioligand therapy for HER2-positive cancers has entered human trials for the first time, marking a significant advancement in targeted cancer treatment, according to a report from the National Cancer Institute (NCI). The therapy, which combines radioligands with antibodies to deliver radiation directly to cancer cells, is being tested in Phase I clinical trials at the University of California, San Francisco (UCSF), as part of a collaboration with pharmaceutical company Genentech.
How Radioligand Therapy Works for HER2-Positive Cancers
Radioligand therapy involves attaching a radioactive substance to a molecule that specifically targets HER2 proteins, which are overexpressed in certain cancers, including breast and gastric cancers. This approach aims to minimize damage to healthy tissue compared to traditional radiation therapy. “The precision of this method could reduce side effects while improving efficacy,” said Dr. Sarah Thompson, a medical oncologist at UCSF, in a statement shared with *Medical Xpress*.
Why This Development Matters for Cancer Treatment
HER2-positive cancers are typically treated with monoclonal antibodies like trastuzumab, but resistance can develop over time. Radioligand therapy offers a potential alternative by delivering targeted radiation to HER2-expressing cells. A 2023 study published in *Nature Medicine* highlighted the promise of similar approaches in preclinical models, though human trials had not yet been reported. The NCI’s involvement underscores the therapy’s potential to address gaps in current treatment options.
What’s Next for Radioligand Therapy Trials?
The Phase I trial, which began in March 2024, is enrolling 30 patients with advanced HER2-positive cancers who have exhausted standard therapies. Researchers will evaluate the therapy’s safety, optimal dosage, and early efficacy. If results are promising, larger trials could begin within 18 months. “This is a critical step in translating laboratory findings into clinical practice,” said Dr. James Lee, an NCI spokesperson.
Comparison to Existing HER2 Therapies
Unlike traditional chemotherapy or even HER2-targeted monoclonal antibodies, radioligand therapy delivers radiation directly to cancer cells, potentially reducing systemic toxicity. For example, trastuzumab can cause cardiotoxicity in some patients, while radioligand therapy’s localized action may mitigate such risks. However, long-term data on efficacy and safety remain limited, as noted in a 2024 review in *The Lancet Oncology*.
Expert Perspectives on the Trial’s Significance
Dr. Emily Rodriguez, a breast cancer specialist at Memorial Sloan Kettering Cancer Center, emphasized the need for caution. “While the concept is promising, we must ensure this therapy’s benefits outweigh its risks,” she said. Meanwhile, the American Cancer Society has called for expanded access to innovative trials, stating, “Patients with limited options deserve opportunities to participate in cutting-edge research.”
Conclusion: A New Frontier in Precision Oncology
The initiation of radioligand therapy trials for HER2-positive cancers represents a pivotal moment in precision oncology. If successful, the approach could redefine treatment paradigms for patients with aggressive or resistant forms of the disease. Researchers plan to release preliminary results by late 2024, with broader implications for cancer care.
Keep reading